Patents by Inventor Dmitry Samarsky

Dmitry Samarsky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oligomeric compound for inhibiting expression of factor XI
    Patent number: 12378552
    Abstract: Products, compositions, and their uses are provided. In particular, nucleic acid products that modulate, in particular interfere with or inhibit, Factor XI (FXI) gene expression are provided. The products can be oligomeric compounds that comprise at least a first region of linked nucleosides having at least a first nucleobase sequence that is at least partially complementary to at least a portion of RNA transcribed from an FXI gene, wherein said first nucleobase sequence is selected from the following sequences, or a portion thereof: SEQ ID NOs 1 to 250.
    Type: Grant
    Filed: April 13, 2022
    Date of Patent: August 5, 2025
    Assignee: Sirnaomics, Inc.
    Inventor: Dmitry Samarsky
  • PRODUCTS AND COMPOSITIONS
    Publication number: 20250043288
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with gene expression or inhibits its expression and therapeutic uses such as for the treatment of disease and disorders.
    Type: Application
    Filed: August 7, 2024
    Publication date: February 6, 2025
    Inventors: Judith Hauptmann, Dmitry Samarsky, Christian Frauendorf
  • Products and compositions
    Patent number: 12084656
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with gene expression or inhibits its expression and therapeutic uses such as for the treatment of disease and disorder.
    Type: Grant
    Filed: March 31, 2021
    Date of Patent: September 10, 2024
    Assignee: SILENCE THERAPEUTICS GMBH
    Inventors: Judith Hauptmann, Dmitry Samarsky, Christian Frauendorf
  • Products and compositions
    Patent number: 11987794
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with target gene expression or inhibit target gene expression and therapeutic uses of such products.
    Type: Grant
    Filed: March 7, 2022
    Date of Patent: May 21, 2024
    Assignee: Silence Therapeutics GMBH
    Inventors: Judith Hauptmann, Dmitry Samarsky, Adrien Weingärtner, Lucas Bethge, Christian Frauendorf, Alison Gallafent
  • RNA interference in ocular indications
    Patent number: 11584933
    Abstract: The present invention relates to ocular administration of sd-rxRNA and rxRNAori molecules.
    Type: Grant
    Filed: May 12, 2020
    Date of Patent: February 21, 2023
    Assignee: Phio Pharmaceuticals Corp.
    Inventors: Lyn Libertine, Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia, Pamela A. Pavco
  • Products and compositions
    Patent number: 11414660
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with target gene expression or inhibit target gene expression and therapeutic uses of such products.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: August 16, 2022
    Assignee: SILENCE THERAPEUTICS GMBH
    Inventors: Judith Hauptmann, Dmitry Samarsky, Adrien Weingärtner, Lucas Bethge, Christian Frauendorf, Alison Gallafent
  • Neutral nanotransporters
    Patent number: 11396654
    Abstract: Neutral lipid formulations for nucleic acid delivery are provided according to the invention. The neutral lipid formulations include hydrophobically modified polynucleotides and fat mixtures. Methods of using the neutral lipid formulations are also provided.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: July 26, 2022
    Assignee: Phio Pharmaceuticals Corp.
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Michelle Miller, Karen G. Bulock
  • Further novel oligonucleotide-ligand conjugates
    Patent number: 11299738
    Abstract: The present invention relates to a compound comprising a modified saccharide moiety conjugated to a nucleic acid. The compound is useful in medicine for RNA interference therapy or for research and diagnostic purposes. In particular, the compound is useful in treating liver disease.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: April 12, 2022
    Assignee: SILENCE THERAPEUTICS GMBH
    Inventors: Dmitry Samarsky, Christian Frauendorf
  • PRODUCTS AND COMPOSITIONS
    Publication number: 20220090067
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with gene expression or inhibits its expression and therapeutic uses such as for the treatment of disease and disorders.
    Type: Application
    Filed: March 31, 2021
    Publication date: March 24, 2022
    Inventors: Judith Hauptmann, Dmitry Samarsky, Christian Frauendorf
  • Reduced size self-delivering RNAI compounds
    Patent number: 11118178
    Abstract: The present invention relates to methods for in vivo administration of sd-rxRNA molecules.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: September 14, 2021
    Assignee: Phio Pharmaceuticals Corp.
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
    Publication number: 20210261968
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal and fibrotic applications.
    Type: Application
    Filed: January 15, 2021
    Publication date: August 26, 2021
    Applicant: Phio Pharmaceuticals Corp.
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, Lyn Libertine, James Cardia, Karen G. Bulock
  • Products and compositions
    Patent number: 11015198
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with gene expression or inhibits its expression and therapeutic uses such as for the treatment of disease and disorders.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: May 25, 2021
    Assignee: SILENCE THERAPEUTICS GMBH
    Inventors: Judith Hauptmann, Dmitry Samarsky, Christian Frauendorf
  • REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS
    Publication number: 20210147849
    Abstract: The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing.
    Type: Application
    Filed: July 21, 2020
    Publication date: May 20, 2021
    Applicant: Phio Pharmaceuticals Corp.
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • RNA INTERFERENCE IN OCULAR INDICATIONS
    Publication number: 20210062195
    Abstract: The present invention relates to ocular administration of sd-rxRNA and rxRNAori molecules.
    Type: Application
    Filed: May 12, 2020
    Publication date: March 4, 2021
    Applicant: Phio Pharmaceuticals Corp.
    Inventors: Lyn Libertine, Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia, Pamela A. Pavco
  • RNA interference in dermal and fibrotic indications
    Patent number: 10913948
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal and fibrotic applications.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: February 9, 2021
    Assignee: Phio Pharmaceuticals Corp.
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, Lyn Libertine, James Cardia, Karen G. Bulock
  • Reduced size self-delivering RNAI compounds
    Patent number: 10876119
    Abstract: The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing. The RNAi constructs may be, for instance, miRNA constructs that are miRNA modulators.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: December 29, 2020
    Assignee: Phio Pharmaceuticals Corp.
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • RNA interference in skin indications
    Patent number: 10815485
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: October 27, 2020
    Assignee: Phio Pharmaceuticals Corp.
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, James Cardia
  • Reduced size self-delivering RNAI compounds
    Patent number: 10774330
    Abstract: The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: September 15, 2020
    Assignee: Phio Pharmaceuticals Corp.
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • RNA interference in ocular indications
    Patent number: 10662430
    Abstract: The present invention relates to ocular administration of sd-rxRNA and rxRNAori molecules.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: May 26, 2020
    Assignee: Phio Pharmaceuticals Corp.
    Inventors: Lyn Libertine, Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia, Pamela A. Pavco
  • REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS
    Publication number: 20200002701
    Abstract: The present invention relates to methods for in vivo administration of sd-rxRNA molecules.
    Type: Application
    Filed: February 7, 2019
    Publication date: January 2, 2020
    Applicant: Phio Pharmaceuticals Corp.
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia